Forest to co-promote Sankyo Benicar
Executive Summary
Forest Laboratories will co-promote Sankyo's anti-hypertensive agent Benicar (olmesartan) in a deal announced Dec. 12. The drug will be detailed by a combined sales force of approximately 1,200 reps. Sankyo filed the Benicar NDA July 27, 2000; FDA deemed the product "approvable" Oct. 24. The companies expect to launch the product in the first half of 2002...
You may also be interested in...
Sankyo/Forest Benicar Launch Set For May; Seventh Angiotensin II Inhibitor
Sankyo and Forest will launch the angiotensin II inhibitorBenicar (olmesartan) with a 1,200-person sales force
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.